[A case report of a patient with hand-foot syndrome induced by bolus 5-fluorouracil therapy].
We present a case of hand-foot syndrome (HFS) induced by bolus 5-fluorouracil (5-FU) therapy. A 54-year-old man received bolus 5-FU for adjuvant treatment of rectal cancer. After second cycle, he presented to the clinic with a rash on the both palms accompanied by symptoms of pain, erythema, swelling, and desquamation consistent with grade 2 HFS. HFS appears more frequently with 5-FU delivered by continuous infusion or with the 5-FU oral derivative capecitabine than with bolus 5-FU therapy. HFS is a leading cause of treatment interruption which may impact on the efficacy of the treatment regimen. This possibility must be considered when patient is receiving a bolus 5-FU treatment, and effective and appropriate patient education is an essential part of management to prevent progression to a more severe grade of toxicity by early detection of HFS.
Matsuyama
Takatoshi
T
Dept. of Surgical Oncology, Tokyo Medical and Dental University Graduate School.
Uetake
Hiroyuki
H
Aoyagi
Haruhiko
H
Kobayashi
Hirotoshi
H
Ishikawa
Toshiaki
T
Iida
Satoru
S
Higuchi
Tetsuro
T
Yasuno
Masamichi
M
Enomoto
Masayuki
M
Sugihara
Kenichi
K
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D005528:Foot / Q000473:pathology*; D006225:Hand / Q000473:pathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology; D013577:Syndrome; D017211:Treatment Failure
D000970:Antineoplastic Agents; D005472:Fluorouracil